Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness

Authors

  • Ahlame Saidi,

    1. INSERM U920, Laboratoire des Mécanismes Moléculaires de l'Angiogenèse, Talence, F-33405, France
    Search for more papers by this author
  • Martin Hagedorn,

    Corresponding author
    1. INSERM U920, Laboratoire des Mécanismes Moléculaires de l'Angiogenèse, Talence, F-33405, France
    2. Univ Bordeaux 1, UFRdeBiologie, Talence, F-33405, France
    • INSERM U920, Université Bordeaux 1, Bât. B2, Av. des Facultés, Talence F-33405, Cedex, France
    Search for more papers by this author
    • Fax: +33-0-5-4000-8705.

  • Nathalie Allain,

    1. INSERM U920, Laboratoire des Mécanismes Moléculaires de l'Angiogenèse, Talence, F-33405, France
    2. Univ Bordeaux 1, UFRdeBiologie, Talence, F-33405, France
    Search for more papers by this author
  • Chiara Verpelli,

    1. CNR Institute of Neuroscience, Department of Pharmacology, University of Milano, Milan, Italy
    2. Neurosurgery, Department of Neurological Sciences, University of Milano, Milan I-20122, Italy
    3. Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan I-20122, Italy
    Search for more papers by this author
  • Carlo Sala,

    1. CNR Institute of Neuroscience, Department of Pharmacology, University of Milano, Milan, Italy
    Search for more papers by this author
  • Lorenzo Bello,

    1. Neurosurgery, Department of Neurological Sciences, University of Milano, Milan I-20122, Italy
    2. Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan I-20122, Italy
    Search for more papers by this author
  • Andreas Bikfalvi,

    1. INSERM U920, Laboratoire des Mécanismes Moléculaires de l'Angiogenèse, Talence, F-33405, France
    2. Univ Bordeaux 1, UFRdeBiologie, Talence, F-33405, France
    Search for more papers by this author
  • Sophie Javerzat

    Corresponding author
    1. INSERM U920, Laboratoire des Mécanismes Moléculaires de l'Angiogenèse, Talence, F-33405, France
    2. Univ Bordeaux 1, UFRdeBiologie, Talence, F-33405, France
    • INSERM U920, Université Bordeaux 1, Bât. B2, Av. des Facultés, Talence F-33405, Cedex, France
    Search for more papers by this author

Abstract

Interleukin-6 (IL6) and vascular endothelial growth factor (VEGFA) are abundantly produced by glioma cells and contribute to malignancy by promoting angiogenesis, cell proliferation and resistance to apoptosis. We compared the effect of inhibiting IL6 and VEGF on U87-derived experimental glioma grown on the chick chorio-allantoic membrane (CAM) or in the brain of xenografted mice. Tumor growth was monitored by biomicroscopy and immunohistology. In vitro, IL6 knockdown had no effect on proliferation but substantially enhanced invasion. In the CAM experimental glioma, IL6 or VEGF knockdown reduced growth and vascularization of the tumors with a comparable efficiency, but increased invasion of residual tumor cells. In contrast, combined IL6/VEGF knockdown not only showed enhanced reduction of tumor growth and angiogenesis but also significantly prevented invasion of residual tumor cells. In mice, combining IL6 knockdown and Avastin™ treatment completely abrogated tumor development and infiltration. Molecular response of tumor cells to single or combined treatment was studied by transcriptomic profiling. Many cell cycle promoting genes and chromatin components were silenced in the double knockdown. In addition, specific migratory signatures detected in tumors under single IL6 or VEGF knockdown were partially erased in combined IL6/VEGF knockdown tumors. Our results show that treatment with a combination of IL6 and VEGF inhibitors brings synergistic antitumoral benefit and reduces global activity of major pathways of cell survival, proliferation and invasiveness in remaining tumor cells that may be induced by using VEGF or IL6 inhibitors alone. © 2009 UICC

Ancillary